Linking In Vitro Intrinsic Dissolution Rate and Thermodynamic Solubility with Pharmacokinetic Profiles of Bedaquiline Long-Acting Aqueous Microsuspensions in Rats

Mol Pharm. 2021 Mar 1;18(3):952-965. doi: 10.1021/acs.molpharmaceut.0c00948. Epub 2021 Jan 5.

Abstract

Pharmacokinetic (PK) profiles of a range of bedaquiline (BDQ) long-acting injectable (LAI) microsuspensions in rats after parenteral (i.e., intramuscular and subcutaneous) administration were correlated with the in vitro intrinsic dissolution rate (IDR) and thermodynamic solubility of BDQ in media varying in surfactant type and concentration to better understand the impact of different nonionic surfactants on the in vivo performance of BDQ LAI microsuspensions. All LAI formulations had a similar particle size distribution. The investigated surfactants were d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS), poloxamer 338, and poloxamer 188. Furthermore, the relevance of medium complexity by using a biorelevant setup to perform in vitro measurements was assessed by comparing IDR and thermodynamic solubility results obtained in biorelevant media and formulation vehicle containing different surfactants in varying concentrations. In the presence of a surfactant, both media could be applied to obtain in vivo representative dissolution and solubility data because the difference between the biorelevant medium and formulation vehicle was predominantly nonsignificant. Therefore, a more simplistic medium in the presence of a surfactant was preferred to obtain in vitro measurements to predict the in vivo PK performance of LAI aqueous suspensions. The type of surfactant influenced the PK profiles of BDQ microsuspensions in rats, which could be the result of a surfactant effect on the IDR and/or thermodynamic solubility of BDQ. Overall, two surfactant groups could be differentiated: TPGS and poloxamers. Most differences between the PK profiles (i.e., maximum concentration observed, time of maximum concentration observed, and area under the curve) were observed during the first 21 days postdose, the time period during which particles in the aqueous suspension are expected to dissolve.

Keywords: aqueous microsuspensions; bedaquiline; intramuscular administration; intrinsic dissolution rate; long-acting injectables; pharmacokinetic profiles in rats; stabilizing excipient; subcutaneous administration; thermodynamic solubility.

MeSH terms

  • Animals
  • Chemistry, Pharmaceutical / methods
  • Diarylquinolines / chemistry*
  • Diarylquinolines / pharmacokinetics*
  • Excipients / chemistry
  • Excipients / pharmacokinetics
  • Male
  • Poloxamer / chemistry
  • Poloxamer / pharmacokinetics
  • Polyethylene Glycols / chemistry
  • Rats
  • Rats, Sprague-Dawley
  • Solubility
  • Surface-Active Agents / chemistry
  • Surface-Active Agents / pharmacokinetics
  • Suspensions / chemistry*
  • Suspensions / pharmacokinetics*
  • Thermodynamics
  • Vitamin E / chemistry
  • Vitamin E / pharmacokinetics
  • Water / chemistry*

Substances

  • Diarylquinolines
  • Excipients
  • Surface-Active Agents
  • Suspensions
  • Water
  • Poloxamer
  • Vitamin E
  • Polyethylene Glycols
  • bedaquiline
  • tocophersolan